mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation

• Naoki Osada,
• Jiro Kikuchi,
• Daisuke Koyama,
• Yoshiaki Kuroda,
• Hiroshi Yasui,
• Joel D. Leverson,
• Yusuke Furukawa

Affiliations

Naoki Osada

Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498

Jiro Kikuchi

Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498

Daisuke Koyama

Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498

Yoshiaki Kuroda

Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japanl; Department of Hematology, National Hospital Organization Hiroshimanishi Medical Center, 4-1-1 Kuba, Otake, Hiroshima 739-0696

Hiroshi Yasui

The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639

Joel D. Leverson

Oncology Discovery, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064

Yusuke Furukawa

Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498